Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company leveraging AI and high-throughput automated experimentation to accelerate drug discovery across multiple therapeutic areas, including oncology, neuroscience, and rare diseases.
| Attribute |
Details |
| Headquarters |
Salt Lake City, Utah, USA |
| Founded |
2013 |
| CEO |
Chris Gibson (Co-founder) |
| Market Cap |
~$500M-$2B (varies) |
| Employees |
~600 |
| Stock Symbol |
RXRX (NASDAQ) |
- 2013: Founded in Salt Lake City, Utah
- 2019: Entered partnership with Roche/Genentech for AI-driven drug discovery
- 2021: IPO on NASDAQ (RXRX)
- 2022: Expanded into neuroscience with focus on neurodegenerative diseases
- 2023: Advanced multiple oncology candidates into clinical trials
- 2024: Continued expansion of CNS pipeline with new partnerships
Recursion's proprietary platform combines multiple cutting-edge technologies:
- Machine Learning & Neural Networks: Advanced algorithms for predicting drug-target interactions, toxicity prediction, and pharmacokinetic modeling
- High-Throughput Automated Screening: State-of-the-art automated laboratories capable of testing millions of compounds in cell-based assays
- Phenotypic Screening: Cell-based assays to identify disease-relevant phenotypes without requiring known molecular targets
- Bioinformatics Integration: Large-scale genomic and transcriptomic data integration for target identification
- Digital Biology: Cell painting and morphological profiling to understand drug effects at the cellular level
Recursion operates one of the largest automated drug discovery laboratories in the industry, featuring:
- Robotic compound handling
- Automated cell culture systems
- High-content imaging
- Integrated data pipelines
Recursion has established a significant presence in neuroscience with multiple programs targeting neurodegenerative diseases:
| Program |
Target |
Stage |
Mechanism |
| REC-994 |
Amyloid/Tau |
Preclinical |
Disease-modifying |
| REC-4881 |
Neuroinflammation |
Preclinical |
Anti-inflammatory |
| Program |
Target |
Stage |
Mechanism |
| REC-4881 |
Alpha-synuclein |
Preclinical |
Protein aggregation modulation |
| TBA |
LRRK2 |
Discovery |
Kinase inhibition |
- Collaboration with Roche/Genentech: Multi-year partnership for AI-driven target identification in CNS disorders
- Neuroinflammation: Programs targeting microglial activation and neuroinflammation in AD and PD
- ALS and Huntington's: Preclinical programs for other neurodegenerative conditions
- Neurodegeneration Focus: Emphasis on protein aggregation, mitochondrial dysfunction, and neuroinflammation
| Partner |
Focus Area |
Year |
Status |
| Roche/Genentech |
AI-driven drug discovery |
2019 |
Active |
| Takeda |
Oncology |
2020 |
Active |
| Biogen |
Neuroscience |
2022 |
Active |
- Multiple academic partnerships for target validation
- University of Utah research collaboration
- Partnerships with leading neuroscience research centers
Recursion's approach to clinical development includes:
- Biomarker-driven patient selection
- Precision medicine approaches
- Adaptive trial designs
- Digital health integration
- IPO Date: February 2021
- Exchange: NASDAQ
- Symbol: RXRX
- Series A-C: $200M+ raised prior to IPO
- IPO Proceeds: ~$400M
- Post-IPO: Strategic investments and partnerships
¶ Competitive Landscape
Recursion competes with other AI-driven drug discovery companies including:
- Exscientia
- Insilico Medicine
- Atomwise
- Relay Therapeutics